Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 30:19:1303-1312.
doi: 10.2147/NDT.S371641. eCollection 2023.

Pimavanserin: A Truly Effective Treatment for Parkinson's Disease Psychosis? A Review of Interventions

Beatrice Heim  1 , Marina Peball  1 , Florian Krismer  1 , Atbin Djamshidian  1 , Klaus Seppi  1
Affiliations
Review

Pimavanserin: A Truly Effective Treatment for Parkinson's Disease Psychosis? A Review of Interventions

Beatrice Heim et al. Neuropsychiatr Dis Treat. .

Abstract

Parkinson's disease (PD) is the second-most common neurodegenerative disorder with a long-term 60% cumulative prevalence of PD psychosis. Medical treatment is limited to few atypical antipsychotic drugs with low affinity to dopamine D2 receptors. In 2016, pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved by the US Food and Drug Administration (FDA) as the only treatment for PD psychosis (PDP). This article provides an overview of the epidemiology, pathophysiology, and treatment options for PDP and illuminates the mode of action and therapy options with pimavanserin and the current study data.

Keywords: Parkinson’s disease; pimavanserin; psychosis.

PubMed Disclaimer

Conflict of interest statement

Dr Beatrice Heim reports grants from from Austrian Science Fund (FWF), personal fees from AbbVie and Novartis, outside the submitted work; Dr Florian Krismer reports grants from National Institutes of Health, grants from Austrian Science Fund (FWF), grants from MSA Coalition, personal fees from Servier, personal fees from Sanofi-Aventis, personal fees from Servier, personal fees from Takeda, outside the submitted work; Dr Atbin Djamshidian reports Honoriaria from Novo Nordisk, Roche, Biogen, and BIAL, outside the submitted work; Dr Klaus Seppi reports personal fees from Ono Pharma UK Ltd, personal fees from Teva, personal fees from UCB Pharma, personal fees from Lundbeck, grants, personal fees from AOP Orphan Pharmaceuticals AG, personal fees from Roche Pharma, personal fees from Grünenthal, personal fees from Stada, personal fees from AbbVie, personal fees from Ever Pharma, personal fees from Licher Pharma, personal fees from Biogen, personal fees from BIAL, grants, personal fees from International Parkinson and Movement Disorders Society, grants from Michael J. Fox Foundation, grants from FWF Austrian Science Fund, outside the submitted work. The authors report no conflicts of interest in this work.

References

    1. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. doi:10.1038/nrdp.2017.13 - DOI - PubMed
    1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi:10.1002/mds.26424 - DOI - PubMed
    1. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180–198. doi:10.1002/mds.27602 - DOI - PMC - PubMed
    1. Weintraub D. Management of psychiatric disorders in Parkinson’s disease: neurotherapeutics - movement disorders therapeutics. Neurotherapeutics. 2020;17(4):1511–1524. doi:10.1007/s13311-020-00875-w - DOI - PMC - PubMed
    1. Divac N, Stojanović R, Savić Vujović K, Medić B, Damjanović A, Prostran M. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with parkinson’s disease. Behav Neurol. 2016;2016:4938154. doi:10.1155/2016/4938154 - DOI - PMC - PubMed